The present invention relates to quinazoline containing zinc-binding
moiety based derivatives that have enhanced and unexpected properties as
inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK)
and their use in the treatment of EGFR-TK related diseases and disorders
such as cancer. The said derivatives may further act as HDAC inhibitors.